Drug Trial Radar · NCT07602530
A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
238
Planned (sponsor's estimate)
Start
Oct 23, 2025
Primary completion
Feb 28, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Astellas Pharma Europe Ltd.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for women in Canada who are in menopause. They have symptoms including hot flashes and night sweats (also known as vasomotor symptoms or VMS). Their own doctor has prescribed fezolinetant for hot flashes and night sweats, as part of routine health care in Canada. In this study, women will be taking tablets of fezolinetant. This study is about recording information only. The women's own doctor decides on treatment, not the study sponsor (Astellas). Women are taking fezolinetant every day for up to 52 weeks (1 year). The main aim is to learn if fezolinetant improves hot flashes and night sweats after 12 weeks. Other aims are to learn if fezolinetant improves hot flashes and night sweats throughout the study. This includes improved sleep and the women's wellbeing. Details are recorded on how satisfied the women are with fezolinetant and if they completed their treatment. This includes reasons for stopping treatment. Any safety issues are recorded. Details about other treatments taken before or with fezolinetant are also recorded.
Conditions
- Hot Flashes
Interventions
FezolinetantDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting improvement in hot flashes/night sweats: Patient Global Impression of Change (PGI-C) VMSTime frame: Week 12
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site CA15002
Montreal, Canada · Recruiting
Site CA15001
Prince Albert, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.